Matthew Shinkle is an Online Content Editor for Healio, a medical news website. He covers a wide range of topics in the field of medicine, including research studies, treatment advancements, and disparities in healthcare. His work has also been featured in the Haddonfield Sun.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Matthew Shinkle's coverage predominantly revolves around healthcare and pharmaceuticals, focusing on scientific research and data-driven insights. Given the emphasis on citing data, pitches to him should provide robust scientific evidence or studies that uncover significant advancements or disparities in cancer treatment. Additionally, given his focus on racial disparities and drug therapy, he may be interested in stories concerning innovative approaches to addressing these issues.
Sources with a deep understanding of clinical trials and medical research could effectively engage Matthew through providing valuable context for new therapies, especially those related to breast cancer, lymphoma, or drugs targeting specific patient populations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mindy Valcarcel, Matthew Shinkle
Although progress has been made, lack of diversity continues to be problematic in trials of immune checkpoint inhibitors, according to study results.
By: Mindy Valcarcel, Matthew Shinkle
Five-fraction stereotactic body radiotherapy proved noninferior to conventional radiotherapy with regard to biochemical or clinical failure for men with localized prostate cancer, according to randomized phase 3 study results.
By: Mindy Valcarcel, Matthew Shinkle
Adjuvant durvalumab significantly improved PFS and OS compared with placebo among patients with limited-stage small cell lung cancer, according to study results presented at ESMO Congress.
By: Matthew Shinkle, Mindy Valcarcel
Survival for people with hepatocellular carcinoma has improved over the last decade, according to study results.
By: Matthew Shinkle, Mindy Valcarcel
The addition of veliparib to adjuvant temozolomide failed to improve OS for patients with newly diagnosed, MGMT -hypermethylated glioblastoma, according to randomized phase 2/phase3 study results.
By: Mindy Valcarcel, Matthew Shinkle
Patients with primary thyroid cancer who received radioactive iodine exhibited increased risk for melanoma and other nonkeratinocyte skin cancers, according to study results.
By: Matthew Shinkle, Mindy Valcarcel
IV lactated Ringer solution should be the preferred volume-expanding fluid for resuscitation of patients with sickle cell disease who experience
By: Mindy Valcarcel, Matthew Shinkle
A shortened adjuvant chemotherapy regimen improved outcomes for infants with unilateral pathologic high-risk retinoblastoma, according to study results.
By: Matthew Shinkle, Mindy Valcarcel
The detection of specific genomic alterations in circulating tumor DNA appeared linked to poorer outcomes among women with metastatic breast cancer, according to study results.
By: Mindy Valcarcel, Matthew Shinkle
The addition of cadonilimab to first-line chemotherapy improved outcomes among certain women with cervical cancer.
(833) 317-6278 
